{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:49:08Z","timestamp":1790419748930,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s00415-015-7703-x","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T05:20:09Z","timestamp":1427865609000},"page":"2201-2213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement"],"prefix":"10.1007","volume":"262","author":[{"given":"Alberto","family":"Albanese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Duzynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Khatkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Relja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Roze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Marie","family":"Skogseid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiya","family":"Timerbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Tzoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,1]]},"reference":[{"key":"7703_CR1","doi-asserted-by":"crossref","first-page":"13019","DOI":"10.1007\/s00415-014-7343-6","volume":"261","author":"PD Charles","year":"2014","unstructured":"Charles PD, Adler CH, Stay M et al (2014) Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol 261:13019\u201313098","journal-title":"J Neurol"},{"key":"7703_CR2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.10127","volume":"17","author":"L Camfield","year":"2002","unstructured":"Camfield L, Ben-Shlomo T, Warner TT (2002) Impact of cervical dystonia on quality of life. Mov Disord 17:838\u2013841","journal-title":"Mov Disord"},{"key":"7703_CR3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2377-11-140","volume":"11","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Adler CH, Charles PD et al (2011) Rational and design of a prospective study: cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurology 11:140","journal-title":"BMC Neurology"},{"issue":"Suppl 1","key":"7703_CR4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0733-8619(08)80005-9","volume":"26","author":"D Swope","year":"2008","unstructured":"Swope D, Barbano R (2008) Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 26(Suppl 1):54\u201365","journal-title":"Neurol Clin"},{"key":"7703_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","volume":"18","author":"A Albanese","year":"2011","unstructured":"Albanese A, Asmus F, Bhatia KP et al (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5\u201318","journal-title":"Eur J Neurol"},{"key":"7703_CR6","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 70:1699\u20131706","journal-title":"Neurology"},{"issue":"no 3","key":"7703_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta2030","volume":"2","author":"MK Murphy","year":"1998","unstructured":"Murphy MK, Black NA, Lamping DL et al (1998) Consensus development methods, and their use in clinical guideline development. Health Technol Assess 2(no 3):1\u201388","journal-title":"Health Technol Assess"},{"key":"7703_CR8","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1474-4422(06)70574-9","volume":"5","author":"J Jankovic","year":"2006","unstructured":"Jankovic J (2006) Treatment of dystonia. Lancet Neurol 5:864\u2013872","journal-title":"Lancet Neurol"},{"key":"7703_CR9","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/mds.21145","volume":"21","author":"C Tassorelli","year":"2006","unstructured":"Tassorelli C, Mancini F, Balloni L et al (2006) Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 21:2240\u20132243","journal-title":"Mov Disord"},{"issue":"9","key":"7703_CR10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(14)70143-7","volume":"13","author":"J Volkmann","year":"2014","unstructured":"Volkmann J, Mueller J, Deuschl G et al (2014) DBS study group for dystonia. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 13(9):875\u2013884. doi: 10.1016\/S1474-4422(14)70143-7 (Epub 2014 Aug 7)","journal-title":"Lancet Neurol"},{"issue":"4","key":"7703_CR11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1468-1331.2011.03591.x","volume":"19","author":"IM Skogseid","year":"2012","unstructured":"Skogseid IM, Ramm-Pettersen J, Volkmann J, Kerty E, Dietrichs E, R\u00f8ste GK (2012) Good long-term efficacy of pallidal stimulation in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol 19(4):610\u2013615. doi: 10.1111\/j.1468-1331.2011.03591.x Epub 2011 Nov 25","journal-title":"Eur J Neurol"},{"key":"7703_CR12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1468-1331.2006.01537.x","volume":"13","author":"A Albanese","year":"2006","unstructured":"Albanese A, Barnes MP, Bhatia KP et al (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS\/MDS-ES task force. Eur J Neurol 13:433\u2013444","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"7703_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1468-1331.2010.03045.x","volume":"17","author":"C Colosimo","year":"2010","unstructured":"Colosimo C, Supa A, Fabbrini G et al (2010) Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 17(Suppl 1):15\u201321","journal-title":"Eur J Neurol"},{"key":"7703_CR14","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s00415-012-6510-x","volume":"259","author":"E Zoons","year":"2012","unstructured":"Zoons E, Dijkgraaf MGW, Dijk JM et al (2012) Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol 259:2519\u20132526","journal-title":"J Neurol"},{"issue":"1","key":"7703_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000008122","volume":"43","author":"D Dressler","year":"2000","unstructured":"Dressler D, Rothwell JC (2000) Electromyograpjc quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 43(1):13\u201316","journal-title":"Eur Neurol"},{"issue":"5","key":"7703_CR16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","volume":"20","author":"NI Meija","year":"2005","unstructured":"Meija NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592\u2013597","journal-title":"Mov Disord"},{"key":"7703_CR17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","volume":"22","author":"C Colosimo","year":"2012","unstructured":"Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum treatment in craniocervical dystonia: a systematic review. Neurotox Res 22:265\u2013273","journal-title":"Neurotox Res"},{"key":"7703_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2012.01.019","volume":"316","author":"D Truong","year":"2012","unstructured":"Truong D (2012) Botulinum toxins in the treatment of primary focal dystonias. J Neurolog Sci 316:9\u201314","journal-title":"J Neurolog Sci"},{"key":"7703_CR19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.41.7.1088","volume":"41","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Leder S, Warner D, Schwartz K (1991) Cervical dystonia: clinical findings and associated movement disorders. Neurology 41:1088\u20131091","journal-title":"Neurology"},{"issue":"3","key":"7703_CR20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-1331.2004.01053.x","volume":"12","author":"IM Skogseid","year":"2005","unstructured":"Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12(3):163\u2013170","journal-title":"Eur J Neurol"},{"key":"7703_CR21","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/mds.20670","volume":"20","author":"IM Skogseid","year":"2005","unstructured":"Skogseid IM, R\u00f8islien J (2005) Claussen, Kerty E. Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 20:1604\u20131609","journal-title":"Mov Disord"},{"issue":"Pt 12","key":"7703_CR22","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1093\/brain\/awh291","volume":"127","author":"M Bove","year":"2004","unstructured":"Bove M, Brichetto G, Abbruzzese G, Marchese R, Schieppate M (2004) Neck proprioception and spatial orientation in cervical dystonia. Brain 127(Pt 12):2764\u20132778","journal-title":"Brain"},{"issue":"13","key":"7703_CR23","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/mds.22693","volume":"24","author":"E Pelosin","year":"2009","unstructured":"Pelosin E, Bove M, Marinelli L, Abbruzzese G, Ghilardi MF (2009) Cervical dystonia affects aimed movements of nonodystonic segments. Mov Disord 24(13):1955\u20131961","journal-title":"Mov Disord"},{"key":"7703_CR24","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/brain\/awr224","volume":"135","author":"M Stamelou","year":"2012","unstructured":"Stamelou M, Edwards MJ, Hallett M, Bhatia KP (2012) The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain 135:1668\u20131681","journal-title":"Brain"},{"issue":"Suppl 2","key":"7703_CR25","first-page":"A259","volume":"46","author":"CL Comella","year":"1996","unstructured":"Comella CL, Stebbins GT, Miller S (1996) Specific dystonic factors contributing to work limitation and disability in cervical dystonia. Neurology 46(Suppl 2):A259","journal-title":"Neurology"},{"issue":"Suppl 1","key":"7703_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0733-8619(08)80003-5","volume":"26","author":"M Stacy","year":"2008","unstructured":"Stacy M (2008) Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 26(Suppl 1):23\u201342","journal-title":"Neurol Clin"},{"key":"7703_CR27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1468-1331.2007.01922.x","volume":"14","author":"IM Skogseid","year":"2007","unstructured":"Skogseid IM, Malt UF, R\u00f8islien J, Kerty E (2007) Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 14:1129\u20131137","journal-title":"Eur J Neurol"},{"issue":"2","key":"7703_CR28","first-page":"95","volume":"22","author":"J Slawek","year":"2007","unstructured":"Slawek J, Friedman A, Potulska A et al (2007) Factors affecting health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 22(2):95\u2013100","journal-title":"Funct Neurol"},{"key":"7703_CR29","author":"H Hefter","year":"2013","unstructured":"Hefter H, Benecke R, Erbguth F et al (2013) An open-label cohort study of the improvement in quality of life and pain in de novo cervical dystonia patients after injections with 500U botulinum toxin (Dysport). BMJ Open. doi: 10.1136\/bmjopen-2112-001853","journal-title":"BMJ Open"},{"key":"7703_CR30","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jnnp.72.5.608","volume":"72","author":"Y Ben-Shlomo","year":"2002","unstructured":"Ben-Shlomo Y, Camfield L, Warner T, ESDE collaborative group (2002) what are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72:608\u2013614","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7703_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/13696998.2011.653726","volume":"15","author":"KD Sethi","year":"2012","unstructured":"Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:1\u20135","journal-title":"J Med Econ"},{"issue":"7","key":"7703_CR32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Bhatia K, Bressman SB et al (2013) Phenomenology and classification of dystonia: a consensus update. Mov Disord 28(7):863\u2013873","journal-title":"Mov Disord"},{"issue":"12","key":"7703_CR33","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/mds.22597","volume":"24","author":"A Albanese","year":"2009","unstructured":"Albanese A, Lalli S (2009) Is this dystonia? Mov Disord 24(12):1725\u20131731","journal-title":"Mov Disord"},{"issue":"11","key":"7703_CR34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/mds.23137","volume":"25","author":"S Lalli","year":"2010","unstructured":"Lalli S, Albanese A (2010) The diagnostic challenge of primary dystonia: evidence from misdiagnosis. Mov Disord 25(11):1619\u20131626","journal-title":"Mov Disord"},{"key":"7703_CR35","volume-title":"Handbook of botulinum toxin treatment","author":"P Moore","year":"2003","unstructured":"Moore P, Naumann M (2003) General and clinical aspects of treatment with botulinum toxin. In: Moore P, Naumann M (eds) Handbook of botulinum toxin treatment, 2nd edn. Blackwell Science, Oxford","edition":"2"},{"key":"7703_CR36","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/mds.25579","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Sorbo FD, Comella C et al (2013) Dystonia rating scale: critique and recommendations. Mov Disord 28:874\u2013883","journal-title":"Mov Disord"},{"key":"7703_CR37","author":"D Dressler","year":"2014","unstructured":"Dressler D, Kupsch A, Seitzinger A, Paus S (2014) The Dystonia Discomfort Scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia. Eur J Neurol. doi: 10.1111\/ene.12330","journal-title":"Eur J Neurol"},{"key":"7703_CR38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.baga.2011.01.001","volume":"1","author":"G Reichel","year":"2011","unstructured":"Reichel G (2011) Cervical dystonia: a new phenomenological classification for botulinum toxin therapy. Basal Ganglia 1:5\u201312","journal-title":"Basal Ganglia"},{"issue":"13","key":"7703_CR39","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.23905","volume":"26","author":"JM Flowers","year":"2011","unstructured":"Flowers JM, Hicklin LA, Marion M-H (2011) Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle. Mov Disord 26(13):2409\u20132414. doi: 10.1002\/mds.23905","journal-title":"Mov Disord"},{"issue":"6","key":"7703_CR40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1468-1331.2000.00161.x","volume":"7","author":"D Dressler","year":"2000","unstructured":"Dressler D (2000) Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur J Neurol 7(6):713\u2013718","journal-title":"Eur J Neurol"},{"key":"7703_CR41","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.parkreldis.2011.06.016","volume":"17","author":"ECH Lim","year":"2012","unstructured":"Lim ECH, Quek AML, Seet RCS (2012) Accurate targeting of botulinum toxin injections: how to and why. Parkinson Rel Dis 17:S34\u2013S39","journal-title":"Parkinson Rel Dis"},{"key":"7703_CR42","unstructured":"Botox SmPC. http:\/\/www.medicines.org.uk\/emc\/medicine\/112"},{"key":"7703_CR43","unstructured":"Dysport SmPC. http:\/\/www.medicines.org.uk\/emc\/medicine\/870"},{"key":"7703_CR44","unstructured":"Xeomin SmPC. http:\/\/www.medicines.org.uk\/emc\/medicine\/20666"},{"key":"7703_CR45","unstructured":"Neurobloc SmPC. http:\/\/www.medicines.org.uk\/emc\/medicine\/20568\/SPC"},{"key":"7703_CR46","unstructured":"Bentovglio AR, Bagella CF, Albanese A (2015) Botulinum toxin in movement disorders. In: Jankovic J, Tolosa E (eds) Parkinson\u2019s disease & Movement Disorders, 6th edn. Wolters Kluver, Philadelphia, pp. 480\u2013495"},{"issue":"10","key":"7703_CR47","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00415-013-7220-8","volume":"261","author":"J Pauw De","year":"2014","unstructured":"De Pauw J, Van der Velden K, Meirte J et al (2014) The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. J Neurol 261(10):1857\u20131865. doi: 10.1007\/s00415-013-7220-8","journal-title":"J Neurol"},{"key":"7703_CR48","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","volume":"40","author":"P Greene","year":"1990","unstructured":"Greene P, Kang U, Fahn S et al (1990) Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40:1213\u20131218","journal-title":"Neurology"},{"key":"7703_CR49","doi-asserted-by":"crossref","first-page":"e000881","DOI":"10.1136\/bmjopen-2012-000881","volume":"2","author":"VP Misra","year":"2012","unstructured":"Misra VP, Ehler E (2012) Zakine B et al Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 2:e000881","journal-title":"BMJ Open"},{"issue":"2","key":"7703_CR50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00702-014-1253-8","volume":"122","author":"D Dressler","year":"2015","unstructured":"Dressler D, Tacik P, Adib Saberi F (2015) Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm 122(2):297\u2013300","journal-title":"J Neural Transm"},{"issue":"12","key":"7703_CR51","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","volume":"120","author":"VGH Evidente","year":"2013","unstructured":"Evidente VGH, Fernandez HH, LeDoux MS et al (2013) A randomized, double-blind study of repeated incobotulinum toxinA (Xeomin\u00ae) in cervical dystonia. J Neural Trans 120(12):1699\u20131707","journal-title":"J Neural Trans"},{"key":"7703_CR52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","volume":"208","author":"CL Comella","year":"2011","unstructured":"Comella CL, Jankovic J, Truong DD et al (2011) Efficacy and safety of incobotulinumtoxin A (NT 201, Xeomin\u00ae botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 208:103\u2013109","journal-title":"J Neurol Sci"},{"key":"7703_CR53","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079904125003962","volume":"20","author":"M Naumann","year":"2004","unstructured":"Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20:981\u2013990","journal-title":"Curr Med Res Opin"},{"key":"7703_CR54","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hed.2880120504","volume":"12","author":"GE Borodic","year":"1990","unstructured":"Borodic GE, Joseph M, Fay L et al (1990) Botulinum toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 12:392\u2013399","journal-title":"Head Neck"},{"key":"7703_CR55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.870090106","volume":"9","author":"GE Borodic","year":"1994","unstructured":"Borodic GE, Ferrante R, Pearce LB, Smith K (1994) Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum-A-toxin injection. Mov Disord 9:31\u201339","journal-title":"Mov Disord"},{"key":"7703_CR56","first-page":"1351","volume":"140","author":"TS Hsu","year":"2004","unstructured":"Hsu TS, Dover JS, Arndt KA (2004) Effect of volume and concentration on the diffusion of botulinum exotoxinA. Arch Dermatol 140:1351\u20131354","journal-title":"Arch Dermatol"},{"key":"7703_CR57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/mus.21343","volume":"40","author":"L Carli","year":"2009","unstructured":"Carli L, Montecucco C, Rossatto O (2009) Assay of diffusion of different botulinum toxin type a formulations. Musc Nerve 40:374\u2013380","journal-title":"Musc Nerve"},{"key":"7703_CR58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0041-0101(03)00196-X","volume":"42","author":"DD Tang-Liu","year":"2003","unstructured":"Tang-Liu DD, Aoki KR, Dolly JO et al (2003) Intramuscular injection of 125I- botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 42:461\u2013469","journal-title":"Toxicon"},{"key":"7703_CR59","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/BTT.S14902","volume":"10","author":"J Frevert","year":"2010","unstructured":"Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics Targets Ther 10:325\u2013332","journal-title":"Biologics Targets Ther"},{"key":"7703_CR60","unstructured":"Benecke R, Moore P, Dressler D, Nauman M (2003) Cervical and axial dystonia. In: Moore P, Nauman M (eds) Handbook of botulinum toxin treatment, chap 8, 2nd edn. Blackwell Science, Oxford"},{"key":"7703_CR61","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1111\/j.1468-1331.2012.03775.x","volume":"19","author":"MA Aranda","year":"2012","unstructured":"Aranda MA, Herranz A, del Val J, Belido S, Garcia-Ruiz P (2012) Botulinum toxin A during pregnancy, still a debate. Eur J Eurol 19:e81\u2013e82","journal-title":"Eur J Eurol"},{"key":"7703_CR62","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J et al (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low antigenicity by mouse protection assay. Mov Disord 23:1353\u20131360","journal-title":"Mov Disord"},{"issue":"suppl 2","key":"7703_CR63","first-page":"S67","volume":"4","author":"D Dressler","year":"1997","unstructured":"Dressler D (1997) Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur J Neurol 4(suppl 2):S67\u2013S70","journal-title":"Eur J Neurol"},{"issue":"4","key":"7703_CR64","first-page":"225","volume":"27","author":"JJ Ferreria","year":"2012","unstructured":"Ferreria JJ, Bhidayasiri R, Colosimo C et al (2012) Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol 27(4):225\u2013230","journal-title":"Funct Neurol"},{"key":"7703_CR65","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-200767050-00003","volume":"67","author":"WH Jost","year":"2007","unstructured":"Jost WH, Blumel J, Grafe S (2007) Botulinum neurotoxin type A free of complexing proteins (XEOMIN\u00ae) in focal dystonia. Drugs 67:669\u2013683","journal-title":"Drugs"},{"key":"7703_CR66","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/mds.21051","volume":"21","author":"C Cordivari","year":"2006","unstructured":"Cordivari C, Misra VP, Vincent A et al (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21:1737\u20131741","journal-title":"Mov Disord"},{"issue":"10","key":"7703_CR67","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/mds.25956","volume":"29","author":"D Dressler","year":"2014","unstructured":"Dressler D, Gessler F, Tacik P, Bigalke H (2014) An enzyme-linked immunosorbent assay for detection of botulinum toxin antibodies. Mov Disord 29(10):1322\u20131324. doi: 10.1002\/mds.25956","journal-title":"Mov Disord"},{"key":"7703_CR68","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/brain\/awt009","volume":"136","author":"RA Walsh","year":"2013","unstructured":"Walsh RA, Sidiropoulos C, Lozano AM et al (2013) Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain 136:761\u2013769","journal-title":"Brain"},{"issue":"12","key":"7703_CR69","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1007\/s00415-008-0031-7","volume":"255","author":"K Wohlfarth","year":"2008","unstructured":"Wohlfarth K, Schwandt I, Wegner F et al (2008) Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 255(12):1932\u20131939","journal-title":"J Neurol"},{"issue":"8","key":"7703_CR70","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20468","volume":"20","author":"A Marchetti","year":"2005","unstructured":"Marchetti A, Magar R et al (2005) Retrospective Evaluation of the Dose of Dysport and BOTOX in the Management of Cervical Dystonia and Blepharospasm: The REAL DOSE Study. Mov Disord 20(8):937\u2013944","journal-title":"Mov Disord"},{"key":"7703_CR71","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1185\/03007990903028203","volume":"25","author":"K Wohlfarth","year":"2009","unstructured":"Wohlfarth K, Sycha T, Ranoux D et al (2009) Dose equivalence in two preparations of botulinum toxin type A: time for a reassessment? Curr Med Res Opin 25:1573\u20131584","journal-title":"Curr Med Res Opin"},{"issue":"3\/4","key":"7703_CR72","first-page":"276","volume":"2","author":"DG Grosset","year":"2013","unstructured":"Grosset DG, Tyrrell EG, Grosset KA (2013) Conversion from Dysport\u00ae to Xeomin\u00ae formulation of botulinum toxin: clinical experience in 257 cases. Botulinum J 2(3\/4):276","journal-title":"Botulinum J"},{"key":"7703_CR73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00702-013-1076-z","volume":"121","author":"D Dressler","year":"2014","unstructured":"Dressler D, Tacik P, Adib Saberi F (2014) Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxin A (Botox\u00ae) and incobotulinumtoxin A (Xeomin\u00ae). J Neural Trans 121:29\u201331","journal-title":"J Neural Trans"},{"key":"7703_CR74","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","volume":"64","author":"T Odergren","year":"1998","unstructured":"Odergren T, Hjaltason H (1998) Kaakkola S et al A double-blind randomised, parallel-group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatr 64:6\u201312","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"3","key":"7703_CR75","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079905X36396","volume":"21","author":"K Bihari","year":"2005","unstructured":"Bihari K (2005) Safety, effectiveness and duration of effect of BOTOX compared with Dysport for blepharospasm, cervical dystonia and hemifacial spasm. Curr Med Res Opin 21(3):433\u2013438","journal-title":"Curr Med Res Opin"},{"key":"7703_CR76","first-page":"459","volume":"72","author":"D Ranoux","year":"2002","unstructured":"Ranoux D et al (2002) Respective potencies of Botox and Dysport: a double blind, randomized, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459\u2013462","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7703_CR77","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.clinthera.2007.07.020","volume":"29","author":"MA Chapman","year":"2007","unstructured":"Chapman MA, Barron R, Tanis DC et al (2007) Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 29:1325\u20131337","journal-title":"Clin Ther"},{"key":"7703_CR78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e3181acefaf","volume":"32","author":"T Hunt","year":"2009","unstructured":"Hunt T, Clarke K (2009) Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharm 32:28\u201331","journal-title":"Clin Neuropharm"},{"key":"7703_CR79","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00702-004-0234-8","volume":"112","author":"WH Jost","year":"2005","unstructured":"Jost WH, Kohl A, Brinkmann S, Comes G (2005) Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT201) compared with commercially available boutlinum toxin type A (BOTOX\u00ae) in healthy volunteers. J Neural Transm 112:905\u2013913","journal-title":"J Neural Transm"},{"key":"7703_CR80","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","volume":"64","author":"R Benecke","year":"2005","unstructured":"Benecke R, Jost WH, Kanovsky P et al (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949\u20131951","journal-title":"Neurology"},{"key":"7703_CR81","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenk\u00e4mper","year":"2006","unstructured":"Roggenk\u00e4mper P, Jost WH, Bihari K et al (2006) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Trans 113:303\u2013312","journal-title":"J Neural Trans"},{"issue":"Suppl 2","key":"7703_CR82","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2009.02877.x","volume":"16","author":"D Dressler","year":"2009","unstructured":"Dressler D (2009) Routine use of Xeomin in patients previously treated with Botox: long-term results. Eur J Neurol 16(Suppl 2):2\u20135","journal-title":"Eur J Neurol"},{"issue":"Suppl 2","key":"7703_CR83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2009.02876.x","volume":"16","author":"R Benecke","year":"2009","unstructured":"Benecke R (2009) Current status of the use of botulinum neurotoxin type A. Eur J Neurol 16(Suppl 2):1. doi: 10.1111\/j.1468-1331.2009.02876.x","journal-title":"Eur J Neurol"},{"issue":"3\/4","key":"7703_CR84","first-page":"217","volume":"2","author":"R Benecke","year":"2013","unstructured":"Benecke R, Hauschke D (2013) IncobotulinumtoxinA demonstrated equivalent efficacy to onabotulinumtoxinA in the treatment of cervical dystonia. Botulinum J 2(3\/4):217","journal-title":"Botulinum J"},{"key":"7703_CR85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14764170260030117","volume":"4","author":"NJ Lowe","year":"2002","unstructured":"Lowe NJ, Yamauchi PS, Lask GP et al (2002) Botulinum toxins types A and B for brow furrows: preliminary experience with type B toxin dosing. J Cosmet Laser Ther 4:15\u201318","journal-title":"J Cosmet Laser Ther"},{"key":"7703_CR86","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.otohns.2005.09.008","volume":"133","author":"A Blitzer","year":"2005","unstructured":"Blitzer A (2005) Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head and Neck Surg 133:836\u2013838","journal-title":"Otolaryngol Head and Neck Surg"},{"key":"7703_CR87","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2133.2010.10085.x","volume":"164","author":"G Kranz","year":"2011","unstructured":"Kranz G, Paul A, Voller B et al (2011) Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study. Br J Dermatol 164:176\u2013181","journal-title":"Br J Dermatol"},{"key":"7703_CR88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","volume":"64","author":"W Poewe","year":"1998","unstructured":"Poewe W, Deuschl G, Nebe A et al (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double-blind placebo controlled dose ranging study of Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatr 64:13\u201317","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7703_CR89","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","volume":"20","author":"D Truong","year":"2005","unstructured":"Truong D, Duane DD, Jankovic J et al (2005) Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomised, double-blind, placebo-controlled study. Mov Disord 20:783\u2013791","journal-title":"Mov Disord"},{"key":"7703_CR90","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","volume":"16","author":"DD Truong","year":"2010","unstructured":"Truong DD, Brodsky M (2010) Lew M et al Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16:316\u2013323","journal-title":"Parkinsonism Relat Disord"},{"key":"7703_CR91","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","volume":"46","author":"JW Brans","year":"1996","unstructured":"Brans JW, Lindeboom R (1996) Snoek JW et al Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46:1066\u20131072","journal-title":"Neurology"},{"key":"7703_CR92","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","volume":"23","author":"EJ Pappert","year":"2008","unstructured":"Pappert EJ, Germanson T, Myobloc\/Neurobloc European Cervical Dystonia Study Group (2008) Botulinum toxin type B vs. type A in toxin naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 23:510\u2013517","journal-title":"Mov Disord"},{"key":"7703_CR93","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","volume":"65","author":"CL Comella","year":"2005","unstructured":"Comella CL, Jankovic J, Shannon KM, Dystonia Study Group et al (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65:1423\u20131429","journal-title":"Neurology"},{"issue":"Suppl 2","key":"7703_CR94","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1468-1331.2010.03130.x","volume":"17","author":"Campbell L Novak","year":"2010","unstructured":"Novak Campbell L, Boyce M, Fung VSC (2010) Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol 17(Suppl 2):94\u2013108","journal-title":"Eur J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-015-7703-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7703-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7703-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T14:04:04Z","timestamp":1566482644000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-015-7703-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,1]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["7703"],"URL":"https:\/\/doi.org\/10.1007\/s00415-015-7703-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,1]]}}}